[Effect of yinchen dandao decoction on plasma fibronectin, biliary thromboxane A2 and prostaglandin I2 in human and animal suffering from acute cholangitis].
OBJECTIVE
To study the therapeutic mechanism of Yinchen Dandao decoction (YCDDD) in treating acute cholangitis.


METHODS
Twenty-four patients with acute cholangitis and 36 cholangiolithiasis patients were randomly classified into the treated group and the control group, and all of these patients had undergone surgical operation. The treated group were given orally YCDDD 3 days after operation for 1 week, and plasma fibronectin (FN), biliary thromboxane A2(TXA2) and prostaglandin I2(PGI2) were measured and compared before and after oral administration of the drug. The models of cholangitis were established in rabbits, which were also randomly grouped into the treated group and the control group, and the same parameters (FN, TXA2, PGI2) were observed as in rabbits.


RESULTS
The level of FN was significantly lower in cholangitis patients than that in the cholangiolithiasis patients before operation (P < 0.01), and compared to the control group, it obviously raised after YCDDD treatment (P < 0.01), the same happened in the cholangiolithiasis patients. The value of TXA2 and PGI2 in the bile was obviously higher (P < 0.01, P < 0.05) in cholangitis patients than those in chlangiolithiasis, and obviously reduced after YCDDD administration (P < 0.01). The level of FN in the treated group and the level of biliary TXA2 and PGI2 in rabbits with cholangitis were significantly higher than those in the control group (P < 0.01).


CONCLUSIONS
YCDDD caused the increase of FN and decrease of biliary TXA2 and PGI2, which might be one of the mechanisms of the drug carried out in cholangitis patients.
Miao
X
X
Second Affiliated Hospital of Hunan Medical University, Changsha 410011.
Zhuang
Z
Z
Liang
L
L
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000208:Acute Disease; D000328:Adult; D000818:Animals; D001646:Bile / Q000378:metabolism; D002761:Cholangitis / Q000188:drug therapy* / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D011817:Rabbits; D011897:Random Allocation; D013929:Thromboxane B2 / Q000378:metabolism*
D004365:Drugs, Chinese Herbal; D005353:Fibronectins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol